| 000 | 01700 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250511201916.0 | ||
| 264 | 0 | _c19911226 | |
| 008 | 199112s 0 0 eng d | ||
| 022 | _a0303-7207 | ||
| 024 | 7 |
_a10.1016/0303-7207(91)90174-q _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSerio, M | |
| 245 | 0 | 0 |
_aDual control by androgens and peptide growth factors of prostatic growth in human benign prostatic hyperplasia. _h[electronic resource] |
| 260 |
_bMolecular and cellular endocrinology _cJun 1991 |
||
| 300 |
_aC77-81 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 | _a5-alpha Reductase Inhibitors |
| 650 | 0 | 4 |
_aAndrogens _xpharmacology |
| 650 | 0 | 4 |
_aAndrostenes _xpharmacology |
| 650 | 0 | 4 |
_aAzasteroids _xpharmacology |
| 650 | 0 | 4 |
_aCarcinoma _xpathology |
| 650 | 0 | 4 |
_aCell Division _xdrug effects |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 |
_aDihydrotestosterone _xmetabolism |
| 650 | 0 | 4 |
_aEpidermal Growth Factor _xphysiology |
| 650 | 0 | 4 | _aFinasteride |
| 650 | 0 | 4 |
_aGonadotropin-Releasing Hormone _xanalogs & derivatives |
| 650 | 0 | 4 |
_aGrowth Substances _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInsulin-Like Growth Factor I _xphysiology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPeptides _xpharmacology |
| 650 | 0 | 4 |
_aProstate _xpathology |
| 650 | 0 | 4 |
_aProstatic Hyperplasia _xdrug therapy |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xpathology |
| 650 | 0 | 4 |
_aTumor Cells, Cultured _xdrug effects |
| 700 | 1 | _aFiorelli, G | |
| 773 | 0 |
_tMolecular and cellular endocrinology _gvol. 78 _gno. 1-2 _gp. C77-81 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/0303-7207(91)90174-q _zAvailable from publisher's website |
| 999 |
_c1725192 _d1725192 |
||